Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

March 16, 2018

Primary Completion Date

October 10, 2024

Study Completion Date

July 16, 2026

Conditions
AIDS-Related LymphomaAnn Arbor Stage II Diffuse Large B-Cell LymphomaAnn Arbor Stage III Diffuse Large B-Cell LymphomaAnn Arbor Stage IV Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Cyclophosphamide

Given IV

DRUG

Doxorubicin Hydrochloride

Given IV

DRUG

Etoposide

Given IV

BIOLOGICAL

Filgrastim

Given SC

DRUG

Ibrutinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pegfilgrastim

Given SC

OTHER

Pharmacological Study

Correlative studies

DRUG

Prednisone

Given PO

BIOLOGICAL

Rituximab

Given IV

DRUG

Vincristine Sulfate

Given IV

Trial Locations (19)

10029

Mount Sinai Hospital, New York

10065

Memorial Sloan Kettering Cancer Center, New York

10467

Montefiore Medical Center - Moses Campus, The Bronx

11553

Memorial Sloan Kettering Nassau, Uniondale

19107

Pennsylvania Hospital, Philadelphia

19111

Fox Chase Cancer Center, Philadelphia

21287

Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

33028

Memorial Hospital West, Pembroke Pines

33136

University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami

43210

Ohio State University Comprehensive Cancer Center, Columbus

60612

John H Stroger Jr Hospital of Cook County, Chicago

University of Illinois College of Medicine - Chicago, Chicago

63110

Siteman Cancer Center at Washington University, St Louis

Washington University School of Medicine, St Louis

92093

UC San Diego Moores Cancer Center, La Jolla

94143

UCSF Medical Center-Parnassus, San Francisco

98101

Virginia Mason Medical Center, Seattle

02118

Boston Medical Center, Boston

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH